{
    "info": {
        "nct_id": "NCT03224507",
        "official_title": "Monoclonal Antibody-Based Sequential Therapy for Deep Remission in Multiple Myeloma - MASTER Trial",
        "inclusion_criteria": "* Age >18 years with no upper age limit\n* Diagnosis of newly diagnosed multiple myeloma with indication for initiation of therapy.\n* Eastern Cooperative Oncology Group (ECOG) performance status 0-2\n* No prior MM-directed therapy except for dexamethasone (up to 160 mg) and/or bortezomib (up to 5.2 mg/m2) and/or cyclophosphamide up to 1000 mg/m2 administered for management of acute manifestations of MM (hypercalcemia, renal impairment, pain) for no longer than 4 weeks prior to enrollment. If subject received any prior therapy, pretreatment parameters necessary for disease characterization and response assessment must be available.\n* Measurable disease meeting at least one of the following criteria:\n\n  1. Serum monoclonal (M) protein ≥1.0 g/dl\n  2. ≥ 200 mg of M protein/24h in the urine\n  3. Serum-free light chain ≥10 mg/dL and abnormal kappa to lambda ratio.\n* Life expectancy ≥12 months.\n* Adequate hepatic function, with serum ALT ≤ 3.5 times the upper limit of normal and serum direct bilirubin ≤ 2 mg/dL (34 μmol/L) within 21 days prior to initiation of therapy.\n* Creatinine clearance (CrCl) ≥ 40 mL/minute within 21 days prior to start of therapy either measured or calculated using a standard formula (eg. Cockcroft and Gault).\n* Written informed consent in accordance with federal, local, and institutional guidelines.\n* Females of childbearing potential must agree to ongoing pregnancy testing and to practice contraception. Male subjects must agree to practice contraception.\n* All subjects must agree to comply with and be enrolled in Revlimid REMS program.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
        "exclusion_criteria": "* Diagnosis of amyloidosis, Crow-Fukase syndrome, Waldenstrom's macroglobulinemia, smoldering MM.\n* Major surgery, radiotherapy or infection requiring therapy within 14 days of starting treatment.\n* Known FEV1 or cDLCO < 50% of predicted.\n* Pregnant or lactating females.\n* Known human immunodeficiency virus infection.\n* Active hepatitis B (Hepatitis B core antibody positive and subsequent Hepatitis B surface antigen positive or Hepatitis B DNA positive) or C infection (Hepatitis C antibody positive and subsequent detectable viral load).\n* Unstable angina or myocardial infarction within 4 months prior to registration, New York Heart Association Class II, III or IV heart failure, uncontrolled angina, history of severe coronary artery disease, severe uncontrolled ventricular arrhythmias, sick sinus syndrome, or electrocardiographic evidence of acute ischemia or Grade 3 conduction system abnormalities unless subject has a pacemaker.\n* Cerebrovascular disease manifested as prior stroke at any time or TIA in the 12 months prior to initiation of therapy\n* Non-hematologic malignancy within the past 3 years with the exception of a) adequately treated basal cell carcinoma, squamous cell skin cancer, or localized thyroid cancer; b) carcinoma in situ of the cervix or breast; c) prostate cancer of Gleason Grade 6 or less with stable prostate-specific antigen levels; or d) cancer considered cured by surgical resection or unlikely to impact survival during the duration of the study, such as localized transitional cell carcinoma of the bladder or benign tumors of the adrenal or pancreas.\n* Significant neuropathy (Grades 3-4, or Grade 2 with pain) within 21 days prior to registration.\n* Known history of allergy to Captisol® (a cyclodextrin derivative used to solubilize carfilzomib).\n* Subjects with pleural effusions requiring thoracentesis or ascites requiring paracentesis within 21 days prior to registration.\n* Contraindication or intolerance to required supportive care medications (Aspirin and Acyclovir).\n* Any other clinically significant medical disease or condition that, in the investigator's opinion, may interfere with protocol adherence or a subject's ability to give informed consent.",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "* All subjects must agree to comply with and be enrolled in Revlimid REMS program.",
            "criterions": [
                {
                    "exact_snippets": "All subjects must agree to comply with and be enrolled in Revlimid REMS program.",
                    "criterion": "Revlimid REMS program participation",
                    "requirements": [
                        {
                            "requirement_type": "agreement to comply",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "enrollment",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Age >18 years with no upper age limit",
            "criterions": [
                {
                    "exact_snippets": "Age >18 years with no upper age limit",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">",
                                        "value": 18,
                                        "unit": "years"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Measurable disease meeting at least one of the following criteria:",
            "criterions": [
                {
                    "exact_snippets": "Measurable disease",
                    "criterion": "disease",
                    "requirements": [
                        {
                            "requirement_type": "measurability",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Eastern Cooperative Oncology Group (ECOG) performance status 0-2",
            "criterions": [
                {
                    "exact_snippets": "Eastern Cooperative Oncology Group (ECOG) performance status 0-2",
                    "criterion": "ECOG performance status",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": "N/A"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 2,
                                        "unit": "N/A"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Life expectancy ≥12 months.",
            "criterions": [
                {
                    "exact_snippets": "Life expectancy ≥12 months",
                    "criterion": "life expectancy",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 12,
                                "unit": "months"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Females of childbearing potential must agree to ongoing pregnancy testing and to practice contraception. Male subjects must agree to practice contraception.",
            "criterions": [
                {
                    "exact_snippets": "Females of childbearing potential must agree to ongoing pregnancy testing",
                    "criterion": "pregnancy testing",
                    "requirements": [
                        {
                            "requirement_type": "agreement to ongoing testing",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Females of childbearing potential ... must ... practice contraception",
                    "criterion": "contraception (females of childbearing potential)",
                    "requirements": [
                        {
                            "requirement_type": "agreement to practice contraception",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Male subjects must agree to practice contraception",
                    "criterion": "contraception (male subjects)",
                    "requirements": [
                        {
                            "requirement_type": "agreement to practice contraception",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. ≥ 200 mg of M protein/24h in the urine",
            "criterions": [
                {
                    "exact_snippets": "≥ 200 mg of M protein/24h in the urine",
                    "criterion": "urinary M protein",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 200,
                                "unit": "mg/24h"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* No prior MM-directed therapy except for dexamethasone (up to 160 mg) and/or bortezomib (up to 5.2 mg/m2) and/or cyclophosphamide up to 1000 mg/m2 administered for management of acute manifestations of MM (hypercalcemia, renal impairment, pain) for no longer than 4 weeks prior to enrollment. If subject received any prior therapy, pretreatment parameters necessary for disease characterization and response assessment must be available.",
            "criterions": [
                {
                    "exact_snippets": "No prior MM-directed therapy except for dexamethasone (up to 160 mg) and/or bortezomib (up to 5.2 mg/m2) and/or cyclophosphamide up to 1000 mg/m2 administered for management of acute manifestations of MM (hypercalcemia, renal impairment, pain) for no longer than 4 weeks prior to enrollment.",
                    "criterion": "prior MM-directed therapy",
                    "requirements": [
                        {
                            "requirement_type": "absence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "exception",
                            "expected_value": [
                                "dexamethasone (up to 160 mg)",
                                "bortezomib (up to 5.2 mg/m2)",
                                "cyclophosphamide up to 1000 mg/m2"
                            ]
                        },
                        {
                            "requirement_type": "indication",
                            "expected_value": [
                                "hypercalcemia",
                                "renal impairment",
                                "pain"
                            ]
                        },
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": "<=",
                                "value": 4,
                                "unit": "weeks"
                            }
                        },
                        {
                            "requirement_type": "time_before_enrollment",
                            "expected_value": {
                                "operator": "<=",
                                "value": 4,
                                "unit": "weeks"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "If subject received any prior therapy, pretreatment parameters necessary for disease characterization and response assessment must be available.",
                    "criterion": "pretreatment parameters for disease characterization and response assessment",
                    "requirements": [
                        {
                            "requirement_type": "availability",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Creatinine clearance (CrCl) ≥ 40 mL/minute within 21 days prior to start of therapy either measured or calculated using a standard formula (eg. Cockcroft and Gault).",
            "criterions": [
                {
                    "exact_snippets": "Creatinine clearance (CrCl) ≥ 40 mL/minute within 21 days prior to start of therapy",
                    "criterion": "creatinine clearance (CrCl)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 40,
                                "unit": "mL/minute"
                            }
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": "within 21 days prior to start of therapy"
                        }
                    ]
                },
                {
                    "exact_snippets": "either measured or calculated using a standard formula (eg. Cockcroft and Gault)",
                    "criterion": "creatinine clearance (CrCl) measurement method",
                    "requirements": [
                        {
                            "requirement_type": "method",
                            "expected_value": [
                                "measured",
                                "calculated using a standard formula (eg. Cockcroft and Gault)"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Adequate hepatic function, with serum ALT ≤ 3.5 times the upper limit of normal and serum direct bilirubin ≤ 2 mg/dL (34 μmol/L) within 21 days prior to initiation of therapy.",
            "criterions": [
                {
                    "exact_snippets": "Adequate hepatic function",
                    "criterion": "hepatic function",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "serum ALT ≤ 3.5 times the upper limit of normal",
                    "criterion": "serum ALT",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3.5,
                                "unit": "times upper limit of normal"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "serum direct bilirubin ≤ 2 mg/dL (34 μmol/L)",
                    "criterion": "serum direct bilirubin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "mg/dL"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "within 21 days prior to initiation of therapy",
                    "criterion": "laboratory test timing",
                    "requirements": [
                        {
                            "requirement_type": "time before therapy",
                            "expected_value": {
                                "operator": "<=",
                                "value": 21,
                                "unit": "days"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. Serum monoclonal (M) protein ≥1.0 g/dl",
            "criterions": [
                {
                    "exact_snippets": "Serum monoclonal (M) protein ≥1.0 g/dl",
                    "criterion": "serum monoclonal (M) protein",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1.0,
                                "unit": "g/dl"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "3. Serum-free light chain ≥10 mg/dL and abnormal kappa to lambda ratio.",
            "criterions": [
                {
                    "exact_snippets": "Serum-free light chain ≥10 mg/dL",
                    "criterion": "serum-free light chain",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 10,
                                "unit": "mg/dL"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "abnormal kappa to lambda ratio",
                    "criterion": "kappa to lambda ratio",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": "abnormal"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Diagnosis of newly diagnosed multiple myeloma with indication for initiation of therapy.",
            "criterions": [
                {
                    "exact_snippets": "Diagnosis of newly diagnosed multiple myeloma",
                    "criterion": "multiple myeloma diagnosis",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis status",
                            "expected_value": "newly diagnosed"
                        }
                    ]
                },
                {
                    "exact_snippets": "indication for initiation of therapy",
                    "criterion": "indication for initiation of therapy",
                    "requirements": [
                        {
                            "requirement_type": "indication",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Written informed consent in accordance with federal, local, and institutional guidelines.",
            "criterions": [
                {
                    "exact_snippets": "Written informed consent in accordance with federal, local, and institutional guidelines.",
                    "criterion": "informed consent",
                    "requirements": [
                        {
                            "requirement_type": "written",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "compliance with guidelines",
                            "expected_value": [
                                "federal",
                                "local",
                                "institutional"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "* Known history of allergy to Captisol® (a cyclodextrin derivative used to solubilize carfilzomib).",
            "criterions": [
                {
                    "exact_snippets": "Known history of allergy to Captisol® (a cyclodextrin derivative used to solubilize carfilzomib)",
                    "criterion": "allergy to Captisol",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Major surgery, radiotherapy or infection requiring therapy within 14 days of starting treatment.",
            "criterions": [
                {
                    "exact_snippets": "Major surgery ... within 14 days of starting treatment",
                    "criterion": "major surgery",
                    "requirements": [
                        {
                            "requirement_type": "time since event",
                            "expected_value": {
                                "operator": ">",
                                "value": 14,
                                "unit": "days"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "radiotherapy ... within 14 days of starting treatment",
                    "criterion": "radiotherapy",
                    "requirements": [
                        {
                            "requirement_type": "time since event",
                            "expected_value": {
                                "operator": ">",
                                "value": 14,
                                "unit": "days"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "infection requiring therapy within 14 days of starting treatment",
                    "criterion": "infection requiring therapy",
                    "requirements": [
                        {
                            "requirement_type": "time since event",
                            "expected_value": {
                                "operator": ">",
                                "value": 14,
                                "unit": "days"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Significant neuropathy (Grades 3-4, or Grade 2 with pain) within 21 days prior to registration.",
            "criterions": [
                {
                    "exact_snippets": "Significant neuropathy (Grades 3-4, or Grade 2 with pain) within 21 days prior to registration.",
                    "criterion": "neuropathy",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": [
                                "Grade 3",
                                "Grade 4"
                            ]
                        },
                        {
                            "requirement_type": "severity_with_pain",
                            "expected_value": "Grade 2 with pain"
                        },
                        {
                            "requirement_type": "time_window",
                            "expected_value": {
                                "operator": "<=",
                                "value": 21,
                                "unit": "days prior to registration"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Active hepatitis B (Hepatitis B core antibody positive and subsequent Hepatitis B surface antigen positive or Hepatitis B DNA positive) or C infection (Hepatitis C antibody positive and subsequent detectable viral load).",
            "criterions": [
                {
                    "exact_snippets": "Active hepatitis B (Hepatitis B core antibody positive and subsequent Hepatitis B surface antigen positive or Hepatitis B DNA positive)",
                    "criterion": "hepatitis B infection",
                    "requirements": [
                        {
                            "requirement_type": "activity",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "core antibody",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "surface antigen or DNA",
                            "expected_value": [
                                "surface antigen positive",
                                "DNA positive"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "C infection (Hepatitis C antibody positive and subsequent detectable viral load)",
                    "criterion": "hepatitis C infection",
                    "requirements": [
                        {
                            "requirement_type": "antibody",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "viral load",
                            "expected_value": "detectable"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Known human immunodeficiency virus infection.",
            "criterions": [
                {
                    "exact_snippets": "Known human immunodeficiency virus infection",
                    "criterion": "human immunodeficiency virus (HIV) infection",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "awareness/status",
                            "expected_value": "known"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Pregnant or lactating females.",
            "criterions": [
                {
                    "exact_snippets": "Pregnant",
                    "criterion": "pregnancy status",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "lactating females",
                    "criterion": "lactation status",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Diagnosis of amyloidosis, Crow-Fukase syndrome, Waldenstrom's macroglobulinemia, smoldering MM.",
            "criterions": [
                {
                    "exact_snippets": "Diagnosis of amyloidosis",
                    "criterion": "amyloidosis",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Diagnosis of ... Crow-Fukase syndrome",
                    "criterion": "Crow-Fukase syndrome",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Diagnosis of ... Waldenstrom's macroglobulinemia",
                    "criterion": "Waldenstrom's macroglobulinemia",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Diagnosis of ... smoldering MM",
                    "criterion": "smoldering multiple myeloma",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Contraindication or intolerance to required supportive care medications (Aspirin and Acyclovir).",
            "criterions": [
                {
                    "exact_snippets": "Contraindication or intolerance to required supportive care medications (Aspirin and Acyclovir)",
                    "criterion": "supportive care medications (Aspirin and Acyclovir)",
                    "requirements": [
                        {
                            "requirement_type": "contraindication",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "intolerance",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Non-hematologic malignancy within the past 3 years with the exception of a) adequately treated basal cell carcinoma, squamous cell skin cancer, or localized thyroid cancer; b) carcinoma in situ of the cervix or breast; c) prostate cancer of Gleason Grade 6 or less with stable prostate-specific antigen levels; or d) cancer considered cured by surgical resection or unlikely to impact survival during the duration of the study, such as localized transitional cell carcinoma of the bladder or benign tumors of the adrenal or pancreas.",
            "criterions": [
                {
                    "exact_snippets": "Non-hematologic malignancy within the past 3 years",
                    "criterion": "non-hematologic malignancy",
                    "requirements": [
                        {
                            "requirement_type": "time since diagnosis",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "years"
                            }
                        },
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Cerebrovascular disease manifested as prior stroke at any time or TIA in the 12 months prior to initiation of therapy",
            "criterions": [
                {
                    "exact_snippets": "Cerebrovascular disease manifested as prior stroke at any time",
                    "criterion": "prior stroke",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "TIA in the 12 months prior to initiation of therapy",
                    "criterion": "transient ischemic attack (TIA)",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "time since event",
                            "expected_value": {
                                "operator": "<=",
                                "value": 12,
                                "unit": "months"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Any other clinically significant medical disease or condition that, in the investigator's opinion, may interfere with protocol adherence or a subject's ability to give informed consent.",
            "criterions": [
                {
                    "exact_snippets": "Any other clinically significant medical disease or condition",
                    "criterion": "clinically significant medical disease or condition",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "in the investigator's opinion, may interfere with protocol adherence",
                    "criterion": "potential to interfere with protocol adherence",
                    "requirements": [
                        {
                            "requirement_type": "investigator judgment",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "in the investigator's opinion, may interfere with ... a subject's ability to give informed consent",
                    "criterion": "potential to interfere with ability to give informed consent",
                    "requirements": [
                        {
                            "requirement_type": "investigator judgment",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Unstable angina or myocardial infarction within 4 months prior to registration, New York Heart Association Class II, III or IV heart failure, uncontrolled angina, history of severe coronary artery disease, severe uncontrolled ventricular arrhythmias, sick sinus syndrome, or electrocardiographic evidence of acute ischemia or Grade 3 conduction system abnormalities unless subject has a pacemaker.",
            "criterions": [
                {
                    "exact_snippets": "Unstable angina",
                    "criterion": "unstable angina",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "myocardial infarction within 4 months prior to registration",
                    "criterion": "myocardial infarction",
                    "requirements": [
                        {
                            "requirement_type": "time since event",
                            "expected_value": {
                                "operator": "<=",
                                "value": 4,
                                "unit": "months"
                            }
                        },
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "New York Heart Association Class II, III or IV heart failure",
                    "criterion": "heart failure (NYHA class)",
                    "requirements": [
                        {
                            "requirement_type": "NYHA class",
                            "expected_value": [
                                "II",
                                "III",
                                "IV"
                            ]
                        },
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "uncontrolled angina",
                    "criterion": "uncontrolled angina",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "history of severe coronary artery disease",
                    "criterion": "severe coronary artery disease",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "severe uncontrolled ventricular arrhythmias",
                    "criterion": "severe uncontrolled ventricular arrhythmias",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "sick sinus syndrome",
                    "criterion": "sick sinus syndrome",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "electrocardiographic evidence of acute ischemia",
                    "criterion": "acute ischemia (on ECG)",
                    "requirements": [
                        {
                            "requirement_type": "evidence on ECG",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "Grade 3 conduction system abnormalities unless subject has a pacemaker",
                    "criterion": "Grade 3 conduction system abnormalities",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "exception",
                            "expected_value": "allowed if subject has a pacemaker"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Known FEV1 or cDLCO < 50% of predicted.",
            "criterions": [
                {
                    "exact_snippets": "Known FEV1 ... < 50% of predicted",
                    "criterion": "FEV1",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 50,
                                "unit": "% of predicted"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Known ... cDLCO < 50% of predicted",
                    "criterion": "cDLCO",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 50,
                                "unit": "% of predicted"
                            }
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [],
    "failed_exclusion": [
        {
            "line": "* Subjects with pleural effusions requiring thoracentesis or ascites requiring paracentesis within 21 days prior to registration.",
            "criterions": [
                {
                    "exact_snippets": "pleural effusions requiring thoracentesis within 21 days prior to registration",
                    "criterion": "pleural effusion",
                    "requirements": [
                        {
                            "requirement_type": "procedure requirement",
                            "expected_value": "requiring thoracentesis"
                        },
                        {
                            "requirement_type": "time window",
                            "expected_value": {
                                "operator": "<=",
                                "value": 21,
                                "unit": "days prior to registration"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "ascites requiring paracentesis within 21 days prior to registration",
                    "criterion": "ascites",
                    "requirements": [
                        {
                            "requirement_type": "procedure requirement",
                            "expected_value": "requiring paracentesis"
                        },
                        {
                            "requirement_type": "time window",
                            "expected_value": {
                                "operator": "<=",
                                "value": 21,
                                "unit": "days prior to registration"
                            }
                        }
                    ]
                }
            ]
        }
    ],
    "failed_miscellaneous": []
}